ClearPoint Neuro マネジメント
マネジメント 基準チェック /34
ClearPoint Neuroの CEO はJoe Burnettで、 Nov2017年に任命され、 の在任期間は 8.75年です。 の年間総報酬は$ 2.81Mで、 20.8%給与と79.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.01%を直接所有しており、その価値は$ 4.94M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と6.9年です。
主要情報
Joe Burnett
最高経営責任者
US$2.8m
報酬総額
| CEO給与比率 | 20.75% |
| CEO在任期間 | 8.8yrs |
| CEOの所有権 | 1.0% |
| 経営陣の平均在職期間 | 3.6yrs |
| 取締役会の平均在任期間 | 6.9yrs |
経営陣の近況
Recent updates
分析記事 • Aug 06
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported And Analysts Have Been Cutting Their Estimates
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) missed earnings with its latest second-quarter results, disappointing...
ナラティブ更新 • Aug 05
CLPT: Huntington’s FDA Path And High ROI Focus Will Support Future Upside
Analysts have trimmed the consolidated price target for ClearPoint Neuro to $22 from $25, reflecting slightly lower modeled revenue growth and profit margins as management focuses on higher ROI projects. These initiatives could weigh on near term results but are still seen as supported by potential partner driven catalysts.
ナラティブ更新 • Jul 10
CLPT: Huntington’s Disease Partnership Will Drive Future Intracranial Procedure Upside
Analysts have lifted their price target on ClearPoint Neuro to $30 from $20, reflecting updated assumptions around a fair value of about $28.33 per share, a modestly lower discount rate, slightly higher modeled revenue growth, and a higher future P/E multiple tied to expectations for more visible revenue opportunities connected to uniQure's AMT-130 program. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed earnings guidance for 2026 and maintained its expected revenue range of $52 million to $56 million.ナラティブ更新 • Jun 26
CLPT: Accelerated Huntington’s Approval Path Will Drive Future Revenue Opportunity
Analysts have lifted their price target on ClearPoint Neuro from $20 to $25, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E in light of ClearPoint's role as a direct beneficiary of the FDA-supported path to accelerated approval for uniQure's AMT-130 in Huntington's disease. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed its earnings guidance for 2026, maintaining expected revenue in the range of US$52 million to US$56 million.Seeking Alpha • Jun 18
ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case
Summary ClearPoint Neuro remains a speculative Buy, offering leveraged exposure to gene therapy commercialization and neurosurgery navigation growth. Recent FDA feedback on uniQure’s AMT-130 renews optimism for near-term revenue, but regulatory and partner execution risks persist. CLPT’s Q1 organic growth slowed, cash burn accelerated, and full-year 2026 revenue guidance ($52–$56M) disappointed versus expectations. Valuation is premium (8.06x EV/sales), justified by 26.8% projected revenue growth, but profitability hinges on partner drug launches and cash management. Read the full article on Seeking Alphaナラティブ更新 • Jun 09
CLPT: Biopharma Partnerships And Intracranial Programs Will Drive Future Upside Potential
Analysts have lifted their price target on ClearPoint Neuro by $2, reflecting updated assumptions around discount rates, profit margins, and long term price-to-earnings (P/E) expectations. What's in the News ClearPoint Neuro reaffirmed revenue guidance for 2026, maintaining an expected range of US$52 million to US$56 million.ナラティブ更新 • May 26
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Upside Potential
Narrative Update: ClearPoint Neuro Analyst Price Target Revision Analysts now set a $22 price target for ClearPoint Neuro, down from $25. This reflects slightly lower modeled revenue growth and profit margins, along with a modestly reduced future P/E assumption, even as recent research highlights the company’s broad base of more than 60 biopharma partners and multiple clinical-stage programs with expedited review designations.ナラティブ更新 • Apr 20
CLPT: Biopharma Partnerships Will Drive Future Intracranial Program Adoption
ClearPoint Neuro's analyst price target has shifted by $2 as analysts weigh the recent FDA feedback on a partner's program in relation to the company's more than 60 active biopharma relationships and multiple expedited intracranial programs. Analyst Commentary Bullish Takeaways Bullish analysts see the reset price target of $18 per share as supported by what they view as a base business valuation of $12 per share, with additional value tied to pipeline and execution on intracranial programs.ナラティブ更新 • Apr 06
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Platform Adoption
Analysts have adjusted their price target on ClearPoint Neuro to $25.00, reflecting updated assumptions around the discount rate, margin expectations, and long term P/E benchmarks following recent research commentary. Analyst Commentary Recent research commentary on ClearPoint Neuro highlights a mix of optimism around the core business and caution linked to regulatory outcomes in partner programs, which feeds directly into updated valuation work and risk assumptions.ナラティブ更新 • Mar 22
CLPT: Broad Biopharma Partnerships And Intracranial Programs Will Drive Future Upside
Analysts have raised their price target on ClearPoint Neuro to $25 from $24, citing the company’s broad base of more than 60 biopharma partners and multiple clinical-stage intracranial programs as key supports for the updated valuation framework. Analyst Commentary Recent research on ClearPoint Neuro reflects a mix of renewed optimism and lingering caution, with analysts updating their valuation work after regulatory feedback on a key partner trial and reassessing the base business.新しいナラティブ • Mar 21
Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders
Catalysts About ClearPoint Neuro ClearPoint Neuro provides minimally invasive neurosurgery systems and tools that support drug, cell and gene therapy delivery to the brain. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Mar 06
CLPT: Broad Biopharma Partnerships Will Support Future Neurology Platform Upside
Analysts have reduced their fair value estimate for ClearPoint Neuro from $29 to $24 and highlighted a lower $18 Street price target, citing higher perceived risk after the FDA feedback on a partner program, while still pointing to a broad biopharma customer base and multiple clinical-stage collaborations as key supports for the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts still see support for the updated valuation from more than 60 active biopharma partners, which suggests a diversified customer base rather than reliance on a single program.
新しいナラティブ • Mar 06
IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential
Catalysts About ClearPoint Neuro ClearPoint Neuro develops and sells neurosurgical navigation, drug delivery and cranial access technologies used across preclinical research, clinical trials and hospital procedures. What are the underlying business or industry changes driving this perspective?分析記事 • Nov 10
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues
The ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price has softened a substantial 39% over the previous 30 days...分析記事 • Nov 03
Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Sep 25
Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 84% after a shaky period...分析記事 • May 04
After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Those holding ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares would be relieved that the share price has rebounded 31% in...Seeking Alpha • Apr 29
ClearPoint Neuro: Fundamentals Continue To Strengthen
Summary ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance. I continue to believe ClearPoint is an attractive investment opportunity, but its high revenue multiple, current lack of profitability and market volatility mean risk is elevated. Read the full article on Seeking Alpha
新しいナラティブ • Mar 29
Cell And Gene Therapy Delivery Will Expand Global Partnerships
Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements.分析記事 • Feb 14
After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have continued their recent momentum with a 25% gain in the last month...分析記事 • Dec 10
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shareholders have had their patience rewarded with a 26% share price jump in the...分析記事 • Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Despite an already strong run, ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have been powering on, with a gain of 28...分析記事 • Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 26% after a shaky period...分析記事 • May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) just released its latest first-quarter results and things are looking bullish...Seeking Alpha • Apr 25
ClearPoint Neuro: Macro-Induced Multiple Compression
Summary ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates. The company is expanding its product portfolio and driving adoption of existing products with new software releases and FDA clearances. The recent capital raise should be sufficient to see the ClearPoint through to profitability. ClearPoint's valuation is modest given the company's rapid growth and expanding product portfolio. Read the full article on Seeking Alpha分析記事 • Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for ClearPoint Neuro is US$4.02 based on 2 Stage Free Cash Flow to Equity Current...分析記事 • Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Shareholders of ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) will be pleased this week, given that the stock price is up 19...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$35m |
| Mar 31 2026 | n/a | n/a | -US$29m |
| Dec 31 2025 | US$3m | US$584k | -US$26m |
| Sep 30 2025 | n/a | n/a | -US$23m |
| Jun 30 2025 | n/a | n/a | -US$22m |
| Mar 31 2025 | n/a | n/a | -US$21m |
| Dec 31 2024 | US$3m | US$538k | -US$19m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$2m | US$518k | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$21m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$2m | US$494k | -US$16m |
| Sep 30 2022 | n/a | n/a | -US$16m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$1m | US$445k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$784k | US$435k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | US$864k | US$366k | -US$6m |
報酬と市場: Joeの 総報酬 ($USD 2.81M ) は、 US市場 ($USD 2.41M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Joeの報酬は増加しましたが、会社は利益を上げていません。
CEO
Joe Burnett (49 yo)
8.8yrs
在職期間
US$2,814,944
報酬
Mr. Joseph Michael Burnett, also known as Joe, has been Chief Executive Officer, President and Director of ClearPoint Neuro, Inc. since November 7, 2017. Mr. Burnett has spent his entire career in medical...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 8.8yrs | US$2.81m | 1.01% $ 4.9m | |
| Chief Financial Officer | 5.6yrs | US$1.25m | 0.34% $ 1.7m | |
| Chief Business Officer | 3.6yrs | US$1.12m | 0.36% $ 1.7m | |
| Chief Operating Officer | 3.8yrs | データなし | 0.22% $ 1.1m | |
| General Counsel & Secretary | 5.3yrs | データなし | データなし | |
| Senior Vice President of Sales & Business Development | less than a year | US$305.12k | データなし | |
| Chief Medical Officer | less than a year | データなし | データなし | |
| Senior Vice President of Regulatory Affairs | less than a year | データなし | データなし | |
| Senior Vice President of Quality | less than a year | データなし | データなし |
3.6yrs
平均在職期間
46yo
平均年齢
経験豊富な経営陣: CLPTの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 8.8yrs | US$2.81m | 1.01% $ 4.9m | |
| Independent Chairman of the Board | 9.3yrs | US$242.65k | 0.43% $ 2.1m | |
| Independent Director | 6.9yrs | US$207.50k | 0.23% $ 1.1m | |
| Independent Director | 5.1yrs | US$220.00k | 0.16% $ 769.7k | |
| Independent Director | 4.8yrs | US$200.00k | 0.21% $ 1.0m | |
| Independent Director | 12.4yrs | US$212.30k | 0.29% $ 1.4m | |
| Director | 6.3yrs | US$192.50k | 0.15% $ 749.1k |
6.9yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: CLPTの 取締役会 は 経験豊富 であると考えられます ( 6.9年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/20 19:55 |
| 終値 | 2026/08/20 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ClearPoint Neuro, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |